What are MTAP deletions?
Homozygous methylthioadenosine phosphorylase deletions are recurring genetic alterations across many tumor types. Yet without testing, they often go undetected and a potentially actionable biomarker hides in plain sight.1
How prevalent is MTAP deletion?
MTAP matters. Test every patient to reveal this important biomarker to inform clinical decision-making.
MTAP=methylthioadenosine phosphorylase.
References: 1. Ngoi NYL, Tang TY, Gaspar CF, et al. Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers. The Oncologist. 2024;29(6):493-503. 2. Tatman M, Brennan DH, Liu C, et al. Genomic characteristics, clinical profiling, and outcomes of advanced pancreatic ductal adenocarcinoma with MTAP-deletion: analyses from a multimodal real-world dataset. Poster presentation at ASCO-GI 2026. Poster H4. 3. Zeng X, Zhao F, Tu X, et al. Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. J Clin Invest. 2025. doi:10.1172/JCI188120 4. Pavlick DC, Rengarajan S, Lee JK, et al. Genomics of MTAP loss in >500,000 solid tumor specimens profiled using comprehensive genomic profiling platforms. JCO Precis Oncol. 2026. doi:10.1200/PO-26-00037 5. Rodon J, Johnson ML, George B, Shah PA, Arbour KC. MTAP deletion in oncogenesis: a synthetic lethality scenario. Cancer Res. 2026;86(7):1558-1569. 6. Bray C, Balcells C, McNeish IA, Keun HC. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Front Oncol. 2023;13:1264785. doi:10.3389/fonc.2023.1264785
Explore ongoing BMS MTAP trials worldwide
